PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
PepGen Inc. (PEPG)
Company Research
Source: Yahoo! Finance
– FREEDOM2 trial open in South Korea, Australia, and New Zealand – – Well-funded with $148.5M of cash as of December 31, 2025, sufficient to fund operations into the second half of 2027 – BOSTON, March 04, 2026 BUSINESS WIRE )--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the quarter and year-ended December 31, 2025, and recent corporate highlights. "2025 was a transformative year for PepGen as the Phase 1 FREEDOM trial delivered compelling data that set a new benchmark for splicing correction in DM1, reinforced our conviction in PGN-EDODM1 as a potential best-in-class treatment, and further demonstrated the differentiated potential of our EDO platform," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "After a single dose, we observed robust
Show less
Read more
Impact Snapshot
Event Time:
PEPG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PEPG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PEPG alerts
High impacting PepGen Inc. news events
Weekly update
A roundup of the hottest topics
PEPG
News
- PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire
- PepGen: Stock Slides On FDA Study Hold - I'm Firmly On The Sidelines [Seeking Alpha]Seeking Alpha
- PepGen muscular dystrophy drug gets ‘surprise' hold from FDA [Yahoo! Finance]Yahoo! Finance
- PepGen GAAP EPS of -$0.27 beats by $0.12 [Seeking Alpha]Seeking Alpha
- US FDA puts partial clinical hold on PepGen's muscle disease drug trial [Yahoo! Finance]Yahoo! Finance
PEPG
Earnings
- 3/4/26 - Beat
PEPG
Sec Filings
- 3/4/26 - Form 8-K
- 3/4/26 - Form S-8
- 3/4/26 - Form 10-K
- PEPG's page on the SEC website